In a joint project, the companies pre-assessed and streamlined the integration of the BD Neopak XtraFlow glass prefillable syringe with the Ypsomed YpsoMate 2.25 auto-injector platform. They aim to address current limitations by enabling the delivery of higher-viscosity biologic drugs in an auto-injector format.
“Cross-supplier collaborations are vital in today’s pharmaceutical ecosystem,” said Patrick Jeukenne, worldwide president of BD Pharmaceutical Systems. “These partnerships can help drive innovation and ensure that systems work by design and over lifecycles, allowing our pharmaceutical partners to get life-saving therapies to patients faster.”
Neopak XtraFlow, the latest addition to BD’s portfolio, features a shorter, 8mm needle length and thinner wall cannula. This optimizes the subcutaneous delivery of higher-viscosity drug profiles. This improvement allows pharmaceutical developers to break design barriers. That enhances flow and usability beyond today’s limits versus a standard half-inch needle.
To support this innovation, Ypsomed plans to expand its YpsoMate 2.25 two-step auto-injector platform to accommodate the new syringe format. That includes adapting parts of the auto-injector for the shorter needle, qualifying tooling and assembly and performing technical testing.
“We are excited to welcome the first pharmaceutical customers to experience the benefits of the BD Neopak XtraFlow glass prefillable syringe with the YpsoMate 2.25 auto-injector,” said Ulrike Bauer, chief business officer of Ypsomed Delivery Systems. “This collaboration underscores our commitment to enhancing patient care through innovative drug delivery solutions.”
